Core Insights - The Chinese medical beauty market is projected to reach a scale of 265 billion yuan by 2024, with a CAGR of 15% from 2017 to 2024 [1] - The number of medical beauty consumers in China is expected to reach 31 million by 2024, with a CAGR of 9% from 2022 to 2024 [1] - The average number of medical beauty treatments per person in China is significantly lower than in developed markets such as South Korea, the United States, and Japan, indicating substantial growth potential [1] Industry Growth Potential - The medical beauty industry is anticipated to maintain steady growth in the high single digits over the next three years, with notable structural opportunities [1] - Certain medical beauty materials still present track dividends, particularly in areas such as natural and recombinant collagen, regenerative microspheres, and emerging materials like PDRN, ECM, silk protein, and PHA [1] - Companies with platform capabilities in upstream product development and downstream medical beauty institutions that possess high reputation and integrated resources are expected to thrive [1]

Group 1 - The medical beauty industry is expected to maintain robust growth in the high single digits over the next three years, with significant structural opportunities within the sector [1] - Certain medical beauty materials still present track dividends, such as natural and recombinant collagen, as well as regenerative microspheres, and materials like PDRN, ECM, silk protein, and PHA that have yet to see the first certification [1] - Companies with platform capabilities in upstream product development and downstream medical beauty institutions that possess high reputation, integrate upstream resources, and maintain differentiation through comprehensive solutions are highlighted as key players [1]